A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market
A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market
Launch of Several Pipeline Oral Products Could Diminish the Market for Injectable Therapies
10-Nov-2014
North America
Description
This market insight provides data for the global multiple sclerosis (MS) market. The analysis looks at MS pharmaceutical pipeline drugs that are currently in the market as well as any drugs that are in Phase III trials and pose a potential threat to competitors. It offers a competitive analysis of these drugs and the forecasted outcome and impact of each of these drugs. Injectable drugs dominate MS drugs currently in the market, but the launch of numerous oral pipeline products can shift this market in favor of oral drugs. The MS market is segmented into relapsing, remitting, secondary progressive, primary progressive, and progressive relapsing MS drugs.
Table of Contents
Key Findings
Recent Market Developments
Recent Market Developments (continued)
Defining Healthcare Trends in the Future
Defining Healthcare Trends in the Future (continued)
Companies to Watch
Methodology and Scope
Introduction
Market Overview—Segmentation
Market Overview—Segmentation (continued)
Market Overview—Segmentation (continued)
Prevalence of MS in Major Market
Prevalence of MS in Major Market (continued)
Physician Guidelines to MS Therapy
Competitive Landscape—Count of Marketed and Pipeline Products
MS Therapeutics Competitive Landscape
Marketed Product Analysis
Marketed Product Analysis (continued)
Pipeline Analysis—Products in Clinical Development
Pipeline Analysis—Products in Clinical Development (continued)
Pipeline Analysis—Products in Clinical Development (continued)
Pipeline Analysis—Products in Clinical Development (continued)
Pipeline Analysis—Products in Clinical Development (continued)
Pipeline Analysis—Products in Clinical Development (continued)
Pipeline Analysis—Products in Clinical Development (continued)
Product Launch Timeline
Patent Expiration Timeline
Marketed Products Clinical Program—AUBAGIO (Teriflunomide)
Marketed Products Clinical Program—Plegridy
Marketed Products Clinical Program—Tysabri
Marketed Products Clinical Program—Tecfidera
Pipeline Products Clinical Program—Ocrelizumab, Ofatumumab
Pipeline Products Clinical Program—Lemtrada
Product Dashboard—Copaxone
Product Dashboard—Avonex (interferon beta-1a)
Product Dashboard—Betaseron/Extavia (interferon beta-1b)
Product Dashboard—Rebif (interferon beta-1a)
Product Dashboard—Tysabri (natalizumab)
Product Dashboard—Gilenya
Product Dashboard—Tecfidera (oral Glatiramer Fumarate)
Product Dashboard—Aubagio (Teriflunomide)
Product Dashboard—Plegridy (BIIB017) (pegylated interferon beta-1a)
Product Dashboard—Lemtrada/Campath 1G (Alemtuzumab)
Product Dashboard—Laquinimod
Product Dashboard—Zenapax (daclizumab)
Product Dashboard—Ocrelizumab
Product Dashboard—AB1010 (Masitinib)
Product Dashboard—Ofatumumab
Conclusions and Recommendations
Legal Disclaimer
The Frost & Sullivan Story
Value Proposition
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Popular Topics
No Index | No |
---|---|
Podcast | No |
Author | Aish Vivekanadan |
WIP Number | NEC3-01-00-00-00 |
Is Prebook | No |